An antibody-drug conjugate given concurrently with stereotactic radiotherapy to treat brain metastases may increase patients risk for symptomatic radiation necrosis, a study suggests.
Histologic analysis did not sufficiently predict treatment response to certain medications, but methods involving gene expression and transcriptome analysis may be more promising.
Datopotamab deruxtecan led to better progression-free survival and safety compared with standard chemotherapy in patients with metastatic HER-2 negative breast cancer.
A neurology professor talks about the need to identify early biomarkers of MS, describes a three-stage model for the disease, and ponders how to define cure in this setting.
The company said on Monday it will voluntarily withdraw its lung cancer therapy from the US after it failed to meet the main goal in a late-stage study.